Skip to main content

Press Releases and Ad-hoc Announcements

02 November 2018	PM: Heidelberg Pharma Announces Several Presentations of Research Results on ATAC Technology at the ASH Annual Meeting 2018	PDF
11 October 2018	PR: Heidelberg Pharma AG: Interim management statement on the first nine months of 2018	PDF
11 October 2018	AH: Partner Magenta Therapeutics Exercises Option To Further Develop a Target Molecule as Antibody Targeted Amanitin Conjugate	PDF
23 August 2018	PR: Heidelberg Pharma AG: Partner Telix Pharmaceuticals Files Phase III Trial for Kidney Cancer Imaging in Europe	PDF
12 July 2018	PR: Heidelberg Pharma reports on first half-year	PDF
26 June 2018	PR: Heidelberg Pharma Reports Outcome Of Annual General Meeting	PDF
30 April 2018	PR: Heidelberg Pharma Presents at Upcoming Conferences and Investor Events	PDF
12 April 2018	Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2018	PDF
09 April 2018	PM: Heidelberg Pharma Presents Proprietary ATAC Technology Platform at Two Scientific Conferences	PDF
22 March 2018	PM: Heidelberg Pharma announces financial figures for fiscal year 2017 and provides business update	PDF
05 March 2018	AH: Heidelberg Pharma and Magenta Therapeutics Sign Exclusive Multi-Target Research Agreement for the Development of Antibody Drug Conjugates	PDF
05 March 2018	PR: Heidelberg Pharma and Magenta Therapeutics Sign Exclusive Multi-Target Research Agreement for the Development of Antibody Drug Conjugates	PDF
01 March 2018	PR: Heidelberg Pharma Signs License Agreement with The University of Texas MD Anderson Cancer Center	PDF
08 January 2018	PR: Heidelberg Pharma AG and Advanced Proteome Therapeutics Progress Collaborative Program	PDF